SMS Pharmaceuticals · NSE: SMSPHARMA · BSE: 532815
Q4 FY22 results · Jan–Mar 2022
SMS Pharmaceuticals reported revenue from operations of ₹60.92 crore and net profit of ₹6.17 crore for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 60.92 | — | — | 121.25 | −49.8% |
| Other income | 0.43 | — | — | 2.13 | −80.0% |
| Total income | 61.35 | — | — | 123.38 | −50.3% |
| Profit before share of associates & JVs and tax | (16.33) | — | — | 16.33 | Turned loss |
| Share of profit/(loss) of associates & JVs | (2.73) | — | 0.00 | ||
| Net profit for the period | 6.17 | — | — | 10.27 | −39.9% |
| EPS, basic (₹) | 0.73 | — | — | 1.07 | −31.8% |
| Net margin (%) | 10.1 | — | 8.5 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 60.92 | 171.29 | −64.4% | 121.25 | −49.8% |
| Other income | 0.43 | 1.30 | −67.3% | 2.13 | −80.0% |
| Total income | 61.35 | 172.59 | −64.5% | 123.38 | −50.3% |
| Profit before tax | (16.17) | 34.31 | Turned loss | 16.56 | Turned loss |
| Net profit for the period | 9.06 | 23.14 | −60.8% | 10.51 | −13.8% |
| EPS, basic (₹) | 1.07 | 2.73 | −60.8% | 1.24 | −13.7% |
| Net margin (%) | 14.9 | 13.5 | 8.7 |
Consolidated
- Filed with BSE
- 13 Jun 2022, 14:05 IST
- Board meeting
- 30 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Jun 2022, 14:05 IST
- Board meeting
- 30 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE